Some biotech stocks have been on fire during these COVID-19 driven times. Hardly a surprise, as these companies are at the forefront of finding a solution to the pandemic and bringing viable treatments, vaccines or adequate tests to market. Case in point: Vaccine maker BioNTech (BNTX), which has been mooted as the provider of a possible coronavirus vaccine, and has seen its shares rising 45% year-to-date.Yet, despite liking the company’s vaccine program, Project Lightspeed, JPMorgan’s Cory Kasimov believes the current valuation is just about right.Kasimov said, “We continue to view BNTX as a potentially disruptive company with access to multiple …read more
Source:: Yahoo Finance
